Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00209014
Status:
TERMINATED
Last Update Posted:
2009-05-07
First Post:
2005-09-13
Brief Title:
Phase II Trial of Thalidomide in RefractoryRelapsed Diffuse Large B-Cell Lymphoma and Hodgkins Disease
Sponsor:
Emory University
Organization:
Emory University
Study Overview
Official Title:
Phase II Trial of Thalidomide in RefractoryRelapsed Diffuse Large B-Cell Lymphoma and Hodgkins Disease
Status:
TERMINATED
Status Verified Date:
2009-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Celgene unable to continue funds
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients who have relapsed or refractory large B-cell lymphoma are being asked to take part in this study The purpose of this study is to find out what effects good and bad the drug thalidomide has on patients and the lymphoma
Detailed Description:
Patients who have relapsed or refractory large B-cell lymphoma are being asked to take part in this study This research is being done because current treatment does not help everyone with this disease The purpose of this study is to find out what effects good and bad the drug thalidomide has on patients and the lymphoma Thalidomide has been shown to have activity against other cancers but is not approved by the FDA for treatment of lymphoma Thalidomide prevents growth of new blood vessels that allow cancer cells to receive nourishment and spread Another reason for doing the study is that researchers want to learn more about how the drug works and whether some patients respond better than others
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None